Efficacy of PTX3 and posaconazole combination in a rat model of invasive pulmonary aspergillosis

Marra, E.; Sousa, V.L.; Gaziano, R.; Pacello, M.L.; Arseni, B.; Aurisicchio, L.; De Santis, R.; Salvatori, G.

Antimicrobial Agents and ChemoTherapy 58(10): 6284-6286

2014


ISSN/ISBN: 1098-6596
PMID: 25070103
DOI: 10.1128/aac.03038-14
Accession: 052898804

Download citation:  
Text
  |  
BibTeX
  |  
RIS

Article/Abstract emailed within 0-6 h
Payments are secure & encrypted
Powered by Stripe
Powered by PayPal

Abstract
Posaconazole is currently used for the prophylaxis of invasive pulmonary aspergillosis (IPA). Limitations to posaconazole usage are drug-drug interactions and side effects. PTX3 is an innate immunity glycoprotein with opsonic activity, proven to be protective in IPA animal models. This study investigated the combination of posaconazole with PTX3. The results indicate synergy between PTX3 and posaconazole against aspergillosis, suggesting that a combination of reduced doses of posaconazole with the immune response enhancer PTX3 might represent a treatment option with a higher therapeutic index than posaconazole.